Recent Updates
Recently added Catalysts
HIMS Positive Sentiment

Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health

Key Takeaway: Hims & Hers has launched Peptides+, a new specialty focusing on personalized health solutions. The service offers clinically-guided protocols that allow eligible customers to receive tailored treatment plans. At launch, customers can access up to five treatments, including Sermorelin and NAD+, based on their specific health needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of Peptides+ targets health at the cellular level.
  • Personalized treatment plans based on clinical visits.
  • Includes five treatments tailored to individual needs.

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC

Frequently Asked Questions

What is Peptides+ by Hims & Hers?

Peptides+ is a new specialty offering personalized health solutions.

What treatments are available with Peptides+?

Treatments include Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine.

How do customers access Peptides+?

Customers must have a clinical visit with a licensed provider.

What is the focus of Peptides+?

Peptides+ targets health at the cellular level through personalized protocols.

Last updated: Nov 18, 2026